Drugs / Meningococcal B vaccine
Meningococcal B vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00937521 | Jul 2009 → Nov 2010 | meningococcal meningitis | Novartis Vaccines | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2020-01-23 | GlaxoSmithKline | Results World’s first meningitis B national infant vaccination programme shows 75% drop in cases over three years gsk.com ↗
According to Public Health England, over a three-year period the total number of meningitis B cases dropped 75 percent. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2020-01-23 | GlaxoSmithKline | World’s first meningitis B national infant vaccination programme shows 75% drop in cases over three years gsk.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Meningococcal B vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00937521 ↗ |
| Known as | 4CMenB | “The licensed meningococcal serogroup B vaccine, 4CMenB (Bexsero(®)), contains recombinant membrane proteins (rMenB) and outer membrane vesicles (OMV) of the New Zealand...” PMID 25424810 ↗ 2014 |
| Known as | Bexsero() | “The licensed meningococcal serogroup B vaccine, 4CMenB (Bexsero(®)), contains recombinant membrane proteins (rMenB) and outer membrane vesicles (OMV) of the New Zealand...” PMID 25424810 ↗ 2014 |
| Modality | Vaccine | “4CMenB vaccine” PMID 35257644 ↗ Mar 2022 |